JP2020504131A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020504131A5 JP2020504131A5 JP2019536488A JP2019536488A JP2020504131A5 JP 2020504131 A5 JP2020504131 A5 JP 2020504131A5 JP 2019536488 A JP2019536488 A JP 2019536488A JP 2019536488 A JP2019536488 A JP 2019536488A JP 2020504131 A5 JP2020504131 A5 JP 2020504131A5
- Authority
- JP
- Japan
- Prior art keywords
- galactosidase
- recombinant human
- weeks
- pharmaceutical composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000005840 alpha-Galactosidase Human genes 0.000 claims 23
- 108010030291 alpha-Galactosidase Proteins 0.000 claims 23
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 239000002552 dosage form Substances 0.000 claims 8
- 230000006866 deterioration Effects 0.000 claims 4
- 208000024720 Fabry Disease Diseases 0.000 claims 3
- 230000003247 decreasing effect Effects 0.000 claims 3
- 230000003907 kidney function Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000000178 monomer Substances 0.000 claims 2
- 229920001515 polyalkylene glycol Polymers 0.000 claims 2
- GRGNVOCPFLXGDQ-TWHXEDJUSA-N (2r,3r,4s,5r,6r)-2-[(2r,3r,4r,5r,6s)-6-[(2r,3s,4r,5r,6r)-6-[(e,2s,3r)-2-amino-3-hydroxyoctadec-4-enoxy]-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](N)[C@H](O)/C=C/CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)O1 GRGNVOCPFLXGDQ-TWHXEDJUSA-N 0.000 claims 1
- 102000002464 Galactosidases Human genes 0.000 claims 1
- 108010093031 Galactosidases Proteins 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 125000005647 linker group Chemical group 0.000 claims 1
- 230000002485 urinary effect Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022192939A JP2023022244A (ja) | 2017-01-05 | 2022-12-01 | 安定化α－ガラクトシダーゼを用いた、ファブリー病の治療のための治療レジメン |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762442537P | 2017-01-05 | 2017-01-05 | |
| US62/442,537 | 2017-01-05 | ||
| PCT/IL2018/050018 WO2018127920A1 (en) | 2017-01-05 | 2018-01-05 | Therapeutic regimen for the treatment of fabry using stabilized alpha-galactosidase |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022192939A Division JP2023022244A (ja) | 2017-01-05 | 2022-12-01 | 安定化α－ガラクトシダーゼを用いた、ファブリー病の治療のための治療レジメン |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020504131A JP2020504131A (ja) | 2020-02-06 |
| JP2020504131A5 true JP2020504131A5 (enExample) | 2021-02-12 |
Family
ID=62790830
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019536488A Pending JP2020504131A (ja) | 2017-01-05 | 2018-01-05 | 安定化α−ガラクトシダーゼを用いた、ファブリー病の治療のための治療レジメン |
| JP2022192939A Pending JP2023022244A (ja) | 2017-01-05 | 2022-12-01 | 安定化α－ガラクトシダーゼを用いた、ファブリー病の治療のための治療レジメン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022192939A Pending JP2023022244A (ja) | 2017-01-05 | 2022-12-01 | 安定化α－ガラクトシダーゼを用いた、ファブリー病の治療のための治療レジメン |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US12194079B2 (enExample) |
| EP (1) | EP3565583A4 (enExample) |
| JP (2) | JP2020504131A (enExample) |
| KR (2) | KR20240042110A (enExample) |
| CN (2) | CN117959455A (enExample) |
| AU (1) | AU2018205891B2 (enExample) |
| BR (1) | BR112019013920A2 (enExample) |
| CA (1) | CA3048151A1 (enExample) |
| CL (1) | CL2019001867A1 (enExample) |
| IL (1) | IL267863A (enExample) |
| MX (1) | MX2019008076A (enExample) |
| NZ (1) | NZ755725A (enExample) |
| WO (1) | WO2018127920A1 (enExample) |
| ZA (1) | ZA201904850B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12020820B1 (en) * | 2017-03-03 | 2024-06-25 | Cerner Innovation, Inc. | Predicting sphingolipidoses (fabry's disease) and decision support |
| CA3141226A1 (en) * | 2019-06-11 | 2020-12-17 | Franklin Johnson | Methods of treating fabry disease in patients having renal impairment |
| AU2021378707A1 (en) * | 2020-11-13 | 2023-06-01 | Hanmi Pharm. Co., Ltd. | Use of therapeutic enzyme fusion protein in prevention and treatment of renal diseases caused by or accompanied by Fabry disease |
| CN116419759A (zh) * | 2020-11-13 | 2023-07-11 | 韩美药品株式会社 | 治疗酶融合蛋白在预防和治疗由法布里病引起或伴有法布里病的神经病中的用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5766897A (en) | 1990-06-21 | 1998-06-16 | Incyte Pharmaceuticals, Inc. | Cysteine-pegylated proteins |
| CA2052728A1 (en) | 1991-10-03 | 1993-04-04 | Guy Ampleman | Glycidyl azide polymer |
| DK1503788T3 (da) * | 2002-04-25 | 2011-10-17 | Shire Human Genetic Therapies | Behandling af alpha-galactosidase A-deficiens |
| WO2006108052A2 (en) * | 2005-04-06 | 2006-10-12 | Genzyme Corporation | Peg and polysialic lysosomal enzyme conjugates via acid labile linkers for therapeutic targeting |
| US9999618B2 (en) * | 2007-04-26 | 2018-06-19 | Amicus Therapeutics, Inc. | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
| AU2008290217B2 (en) | 2007-08-20 | 2013-09-05 | Protalix Ltd. | Saccharide-containing protein conjugates and uses thereof |
| US20120230974A1 (en) | 2009-11-17 | 2012-09-13 | Protalix Ltd | Alkaline alpha galactosidase for the treatment of fabry disease |
| US9194011B2 (en) * | 2009-11-17 | 2015-11-24 | Protalix Ltd. | Stabilized alpha-galactosidase and uses thereof |
| BR112012022029B1 (pt) * | 2010-03-02 | 2022-10-11 | Protalix Ltd | Estrutura de proteina multimérica, seu uso e processo para preparação da estrutura de proteína multimérica |
| BR112013018516B1 (pt) | 2011-01-20 | 2023-11-07 | Protalix Ltd | Construto de expressão de ácido nucleico, método de produção de uma proteína alfa-galactosidase humana recombinante, proteína alfagalactosidase humana, composição farmacêutica, e, uso de uma proteína alfagalactosidase humana ou de uma composição |
| WO2014120900A1 (en) * | 2013-01-31 | 2014-08-07 | Icahn School Of Medicine At Mount Sinai | Enhanced therapeutic regimens for treating fabry disease |
-
2018
- 2018-01-05 MX MX2019008076A patent/MX2019008076A/es unknown
- 2018-01-05 EP EP18736643.0A patent/EP3565583A4/en active Pending
- 2018-01-05 KR KR1020247008410A patent/KR20240042110A/ko not_active Ceased
- 2018-01-05 WO PCT/IL2018/050018 patent/WO2018127920A1/en not_active Ceased
- 2018-01-05 AU AU2018205891A patent/AU2018205891B2/en active Active
- 2018-01-05 BR BR112019013920A patent/BR112019013920A2/pt unknown
- 2018-01-05 CN CN202410140178.XA patent/CN117959455A/zh active Pending
- 2018-01-05 NZ NZ755725A patent/NZ755725A/en unknown
- 2018-01-05 US US16/476,084 patent/US12194079B2/en active Active
- 2018-01-05 CA CA3048151A patent/CA3048151A1/en active Pending
- 2018-01-05 KR KR1020197023039A patent/KR20190103320A/ko not_active Ceased
- 2018-01-05 CN CN201880016068.5A patent/CN110381987A/zh active Pending
- 2018-01-05 JP JP2019536488A patent/JP2020504131A/ja active Pending
-
2019
- 2019-07-04 CL CL2019001867A patent/CL2019001867A1/es unknown
- 2019-07-04 IL IL267863A patent/IL267863A/en unknown
- 2019-07-24 ZA ZA2019/04850A patent/ZA201904850B/en unknown
-
2022
- 2022-12-01 JP JP2022192939A patent/JP2023022244A/ja active Pending
-
2025
- 2025-01-10 US US19/015,746 patent/US20250134968A1/en active Pending